Showing 1-10 of 756 results for "".
The Importance of Diversity in Clinical Trials
https://practicaldermatology.com/issues/april-2025/the-importance-of-diversity-in-clinical-trials/35606/The disproportionate representation of certain segments of the population in clinical trials is no secret, and research has shown that psoriasis studies are the least racially diverse of all dermatology studies in the US.Navigating Industry: Tips for Successful Relationships and Partnerships
https://practicaldermatology.com/issues/january-february-2025/navigating-industry-tips-for-successful-relationships-and-partnerships/32976/Dermatology is no longer confined to the physician-patient interaction in a busy clinic, private practice office, or academic center.June Issue: Melanoma Updates - Epidemiology, Diagnostics, and Treatment
https://practicaldermatology.com/issues/may-june-2025/melanoma-updates-epidemiology-diagnostics-and-treatment/35917/In this article, we review the latest changes in melanoma incidence and mortality, highlight key disparities among minority populations, and summarize emerging trends in technology and treatment that are reshaping the future of melanoma care.Evaluation and Management of Melanocytic Nevi in Children
https://practicaldermatology.com/topics/general-topics/evaluation-and-management-of-melanocytic-nevi-in-children/21570/Children with melanocytic nevi require proper counseling to discuss the risk for melanoma.- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- Núria Perez-Cullell Appointed CEO of Pierre Fabre Dermo-Cosmeticshttps://practicaldermatology.com/news/nria-perez-cullell-appointed-ceo-of-pierre-fabre-dermo-cosmetics/2457679/Ms. Núria PerezCullell is the new CEO of The Pierre Fabre Group’s Pierre Fabre Dermo-Cosmetics (PFDC) subsidiary. This appointment will take effect on August 20, 2018. Núria Perez-Cullell will take over from Mr. Eric Ducournau, whose appointment to the position of Pier
- Vehicles, Infectious Disease, and Acne Updates from Day 2 at DERM2019https://practicaldermatology.com/news/vehicles-infectious-disease-and-acne-updates-from-day-2-at-derm2019/2460099/The DERM2019 NP/PA CME Conference continued to delight audiences with esteemed faculty presenters, including those who presented Friday, including April Armstrong, David Cohen, Kara Gooding, Joseph Gorelick, Julie Harper, Jayme Heim, George Keough, Leon Kircik, Kristine Kucera, Gilly Munavalli, T
- Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019https://practicaldermatology.com/news/psoriasis-psoriatic-arthritis-and-ad-updates-from-day-1-at-derm2019/2460098/The first day of the DERM2019 NP/PA CME Conference kicked off with a bang! Exciting talks and lively panel discussions from April Armstrong, David Cohen, Adam Friedman, Kara Gooding, and Joe Gorelick were the mainstay of the day. Psoriasis Pathogenesis and Treatment T
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Prev
- Next